Literature DB >> 9781963

The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society.

C J Mettlin1, G P Murphy, D S Rosenthal, H R Menck.   

Abstract

BACKGROUND: Prostate carcinoma incidence has been declining since 1992 after a period of marked increase. Recent data from the National Cancer Data Base (NCDB) were examined to assess changes in prostate carcinoma patient characteristics and disease and treatment patterns coincidental to this decline. The NCDB is a program of the American College of Surgeons Commission on Cancer and the American Cancer Society that collects timely data from institutions representing every level of cancer care.
METHODS: Data from 1114 hospitals regarding 103,979 patients diagnosed with prostate carcinoma in 1992 and from 1144 hospitals regarding 72,337 patients diagnosed in 1995 were studied. Patient and disease characteristics studied included age, race, American Joint Committee on Cancer stage, and tumor histologic grade. Trends in treatment and variations in treatment by region also were examined.
RESULTS: The average age at diagnosis declined by 2 years over the period studied and the proportion of patients identified as African-American increased from 8.8% to 11.8%. The proportion of patients diagnosed with localized disease and the proportion of tumors of moderately differentiated histologic grade increased. The overall proportion of patients treated by radical prostatectomy increased and the use of external beam radiation treatment decreased. Substantial regional variation in treatment patterns was observed. The Pacific and Mountain state regions of the U. S. had the highest proportions of patients treated by radical prostatectomy although increases were occurring in other regions. Use of external beam radiation treatment was highest in the Northeast and Southeast states and was declining in the majority of regions. Use of brachytherapy radiation treatment by implantation of radioactive seeds was infrequent but increasing.
CONCLUSIONS: Comparison of the basic characteristics of prostate carcinoma data from 1992 and 1995 shows that patients are being diagnosed at younger ages and earlier stages, the proportion of African-Americans has increased, and more patients are being treated for cure. Regional differences in patterns of care persist but may be moderating. The annual prostate carcinoma death rate in the U.S. has declined an average of 1% per year since 1990.

Entities:  

Mesh:

Year:  1998        PMID: 9781963     DOI: 10.1002/(sici)1097-0142(19981015)83:8<1679::aid-cncr24>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  PSA screening: the bottom line.

Authors:  M M Elhilali
Journal:  CMAJ       Date:  2000-03-21       Impact factor: 8.262

2.  Patterns of prostate cancer treatment by clinical stage and age.

Authors:  D Meltzer; B Egleston; I Abdalla
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

Review 3.  Methods for volume assessment of prostate cancer.

Authors:  Heinz-Peter Schlemmer; Stefan Corvin
Journal:  Eur Radiol       Date:  2004-02-06       Impact factor: 5.315

4.  MR-compatible assistance system for punction in a high-field system: device and feasibility of transgluteal biopsies of the prostate gland.

Authors:  Stephan Zangos; Christopher Herzog; Katrin Eichler; Renate Hammerstingl; Andreas Lukoschek; Stefanie Guthmann; Bernd Gutmann; Uwe Joseph Schoepf; Phillip Costello; Thomas J Vogl
Journal:  Eur Radiol       Date:  2006-10-10       Impact factor: 5.315

5.  Differential dose contributions on total dose distribution of (125)I brachytherapy source.

Authors:  B Camgöz; G Yeğin; M N Kumru
Journal:  Rep Pract Oncol Radiother       Date:  2010-05-26

6.  Knowledge, beliefs and barriers associated with prostate cancer prevention and screening behaviors among African-American men.

Authors:  Deborah E Blocker; LaHoma Smith Romocki; Kamilah B Thomas; Belinda L Jones; Ethel Jean Jackson; LaVerne Reid; Marci K Campbell
Journal:  J Natl Med Assoc       Date:  2006-08       Impact factor: 1.798

7.  Novel diagnostic biomarkers for prostate cancer.

Authors:  Chikezie O Madu; Yi Lu
Journal:  J Cancer       Date:  2010-10-06       Impact factor: 4.207

8.  Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell.

Authors:  D W Cui; Y J Cheng; S W Jing; G G Sun
Journal:  Tumour Biol       Date:  2013-11-29

9.  MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results.

Authors:  Stephan Zangos; Katrin Eichler; Kerstin Engelmann; Mukhtiar Ahmed; Sebastian Dettmer; Christopher Herzog; Wasilios Pegios; A Wetter; Thomas Lehnert; Martin G Mack; Thomas J Vogl
Journal:  Eur Radiol       Date:  2004-09-04       Impact factor: 5.315

10.  [Survival of patients diagnosed with prostate cancer and monitored in primary care].

Authors:  Gabriel J Díaz Grávalos; Gerardo Palmeiro Fernández; Inmaculada Casado Górriz; Margarita Arandia García; Susana Alvarez Araújo; Mónica González Dacosta
Journal:  Aten Primaria       Date:  2007-11       Impact factor: 1.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.